Compare iShares Gold Trust (IAU) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Gold Trust vs Stryker Corporation — how do they compare? iShares Gold Trust trades at $77.69, while Stryker Corporation trades at $309.94 (market cap $120.60B). The key difference: Stryker Corporation pays a 1.12% dividend while iShares Gold Trust pays none, and iShares Gold Trust is trading nearer its 52-week high, Stryker Corporation nearer its low. Which is the better fit depends on your goals.
| IAU | SYK | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Technology |
52-Week High | $101.57 | $403.53 |
52-Week Low | $61.62 | $282.58 |
Market Cap | — | $120.60B |
Enterprise Value | — | $132.36B |
Dividend Yield | — | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAU, the iShares Gold Trust ETF, trades at $75.35, down 0.2% with a bearish technical signal from moving averages. The ETF tracks physical gold prices, which have shown volatility amid Middle East tensions and shifting Fed rate expectations. Recent institutional activity includes Eurizon Asset Management acquiring 482,015 shares in Q1 2026 while AlTi Global reduced its position by 1.3%.
Gold's outlook balances strong central bank demand against interest rate pressures. The risk/reward appears favorable with limited downside, though Fed policy remains the primary driver. Physical gold demand from Asian markets provides support, but higher rates could continue to cap near-term gains.
Stryker (SYK) trades at $319.14, down 0.23% with a bearish technical signal despite strong fundamentals. The company reported $25.12B revenue and $3.25B net income for 2025, maintaining robust margins. Recent news highlights Mako RPS launch expansion in robotic surgery, while Q1 2026 earnings missed expectations due to a temporary cyber disruption, though full-year guidance remains unchanged.
Outlook remains positive with 74% analyst buy ratings and a $388.44 consensus price target implying 22% upside. Key risks include competitive pressures and execution challenges from recent cybersecurity issues. The stock presents a growth opportunity in med-tech innovation, trading below historical valuation multiples with healthy cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
